Literature DB >> 25913211

A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study.

Atsushi Hashizume1, Masahisa Katsuno1, Keisuke Suzuki1, Haruhiko Banno2, Noriaki Suga1, Tomoo Mano1, Amane Araki1, Yasuhiro Hijikata1, Christopher Grunseich3, Angela Kokkinis3, Akihiro Hirakawa4, Hirohisa Watanabe1, Masahiko Yamamoto5, Kenneth H Fischbeck3, Gen Sobue6.   

Abstract

We aimed to develop, validate, and evaluate a disease-specific outcome measure for SBMA: the Spinal and Bulbar Muscular Atrophy Functional Rating Scale (SBMAFRS). We examined the Japanese version (SBMAFRS-J) in 80 Japanese SBMA subjects to evaluate its validity and reliability. We then assessed this scale longitudinally in 41 additional SBMA subjects. The English version (SBMAFRS-E) was also tested in 15 US subjects. The total score of the SBMAFRS-J was distributed normally without an extreme ceiling or floor effect. For SBMAFRS-J, the high intra- and inter-rater agreement was confirmed (intra-class correlation coefficients [ICCs] 0.910 and 0.797, respectively), and internal consistency was satisfactory (Cronbach's alpha 0.700-0.822). In addition, SBMAFRS-J demonstrated concurrent, convergent, and discriminant validity, except for the respiratory subscale. The inter-rater reliability and internal consistency of SBMAFRS-E were also satisfactory. Longitudinally, SBMAFRS-J showed a higher sensitivity to disease progression than the existing clinical measures. In conclusion, we developed and validated a disease-specific functional rating scale for SBMA in both Japanese and English versions, although it needs to be re-assessed in interventional studies with a larger sample size including English speaking subjects.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Functional rating scale; Motor neuron disease; Spinal and bulbar muscular atrophy; Validation

Mesh:

Year:  2015        PMID: 25913211      PMCID: PMC5608513          DOI: 10.1016/j.nmd.2015.03.008

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  36 in total

1.  Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Noriaki Suga; Fumiaki Tanaka; Gen Sobue
Journal:  J Neurol       Date:  2011-09-28       Impact factor: 4.849

2.  Responsiveness of different rating instruments in spinocerebellar ataxia patients.

Authors:  T Schmitz-Hübsch; R Fimmers; M Rakowicz; R Rola; E Zdzienicka; R Fancellu; C Mariotti; C Linnemann; L Schöls; D Timmann; A Filla; E Salvatore; J Infante; P Giunti; R Labrum; B Kremer; B P C van de Warrenburg; L Baliko; B Melegh; C Depondt; J Schulz; S Tezenas du Montcel; T Klockgether
Journal:  Neurology       Date:  2010-02-23       Impact factor: 9.910

3.  Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients.

Authors:  Naoki Atsuta; Hirohisa Watanabe; Mizuki Ito; Haruhiko Banno; Keisuke Suzuki; Masahisa Katsuno; Fumiaki Tanaka; Akiko Tamakoshi; Gen Sobue
Journal:  Brain       Date:  2006-04-18       Impact factor: 13.501

4.  [Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis].

Authors:  E Oda; Y Ohashi; K Tashiro; Y Mizuno; H Kowa; N Yanagisawa
Journal:  No To Shinkei       Date:  1996-11

5.  Pilot trial of clenbuterol in spinal and bulbar muscular atrophy.

Authors:  Giorgia Querin; Carla D'Ascenzo; Enrico Peterle; Mario Ermani; Luca Bello; Paola Melacini; Lucia Morandi; Letizia Mazzini; Vincenzo Silani; Monika Raimondi; Jessica Mandrioli; Silvia Romito; Corrado Angelini; Elena Pegoraro; Gianni Sorarù
Journal:  Neurology       Date:  2013-05-03       Impact factor: 9.910

Review 6.  Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.

Authors:  F Guillemin; C Bombardier; D Beaton
Journal:  J Clin Epidemiol       Date:  1993-12       Impact factor: 6.437

7.  Reliability and validity of the CMT neuropathy score as a measure of disability.

Authors:  M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

8.  Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial.

Authors:  Lindsay E Fernández-Rhodes; Angela D Kokkinis; Michelle J White; Charlotte A Watts; Sungyoung Auh; Neal O Jeffries; Joseph A Shrader; Tanya J Lehky; Li Li; Jennifer E Ryder; Ellen W Levy; Beth I Solomon; Michael O Harris-Love; Alison La Pean; Alice B Schindler; Cheunju Chen; Nicholas A Di Prospero; Kenneth H Fischbeck
Journal:  Lancet Neurol       Date:  2011-01-06       Impact factor: 44.182

9.  The ALSSQOL: balancing physical and nonphysical factors in assessing quality of life in ALS.

Authors:  Z Simmons; S H Felgoise; B A Bremer; S M Walsh; D J Hufford; M B Bromberg; W David; D A Forshew; T D Heiman-Patterson; E C Lai; L McCluskey
Journal:  Neurology       Date:  2006-11-14       Impact factor: 9.910

10.  Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial.

Authors:  Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Yu Takeuchi; Motoshi Kawashima; Ichiro Yabe; Hidenao Sasaki; Masashi Aoki; Mitsuya Morita; Imaharu Nakano; Kazuaki Kanai; Shoichi Ito; Kinya Ishikawa; Hidehiro Mizusawa; Tomotaka Yamamoto; Shoji Tsuji; Kazuko Hasegawa; Takayoshi Shimohata; Masatoyo Nishizawa; Hiroaki Miyajima; Fumio Kanda; Yasuhiro Watanabe; Kenji Nakashima; Akira Tsujino; Taro Yamashita; Makoto Uchino; Yasushi Fujimoto; Fumiaki Tanaka; Gen Sobue
Journal:  Lancet Neurol       Date:  2010-08-04       Impact factor: 44.182

View more
  23 in total

1.  Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis.

Authors:  Daisuke Ito; Atsushi Hashizume; Yasuhiro Hijikata; Shinichiro Yamada; Yohei Iguchi; Madoka Iida; Yoshiyuki Kishimoto; Hideyuki Moriyoshi; Akihiro Hirakawa; Masahisa Katsuno
Journal:  J Neurol       Date:  2019-08-27       Impact factor: 4.849

2.  Development of a functional composite for the evaluation of spinal and bulbar muscular atrophy.

Authors:  Tomonori Inagaki; Atsushi Hashizume; Yasuhiro Hijikata; Shinichiro Yamada; Daisuke Ito; Yoshiyuki Kishimoto; Ryota Torii; Hiroyuki Sato; Akihiro Hirakawa; Masahisa Katsuno
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

Review 3.  Clinical Trials in Spinal and Bulbar Muscular Atrophy-Past, Present, and Future.

Authors:  Patrick Weydt; Anna Sagnelli; Angela Rosenbohm; Pietro Fratta; Pierre-François Pradat; Albert C Ludolph; Davide Pareyson
Journal:  J Mol Neurosci       Date:  2015-11-14       Impact factor: 3.444

4.  Towards a European Registry and Biorepository for Patients with Spinal and Bulbar Muscular Atrophy.

Authors:  Davide Pareyson; Pietro Fratta; Pierre-François Pradat; Gianni Sorarù; Josef Finsterer; John Vissing; Manu E Jokela; Bjarne Udd; Albert C Ludolph; Anna Sagnelli; Patrick Weydt
Journal:  J Mol Neurosci       Date:  2016-01-07       Impact factor: 3.444

5.  Validation of the Italian version of the SBMA Functional Rating Scale as outcome measure.

Authors:  Giorgia Querin; Elisa DaRe; Ilaria Martinelli; Luca Bello; Cinzia Bertolin; Davide Pareyson; Caterina Mariotti; Elena Pegoraro; Gianni Sorarù
Journal:  Neurol Sci       Date:  2016-07-21       Impact factor: 3.307

6.  A randomized controlled trial of exercise in spinal and bulbar muscular atrophy.

Authors:  Joseph A Shrader; Ilona Kats; Angela Kokkinis; Cris Zampieri; Ellen Levy; Galen O Joe; Joshua G Woolstenhulme; Bart E Drinkard; Michaele R Smith; Willie Ching; Laboni Ghosh; Derrick Fox; Sungyoung Auh; Alice B Schindler; Kenneth H Fischbeck; Christopher Grunseich
Journal:  Ann Clin Transl Neurol       Date:  2015-05-07       Impact factor: 4.511

7.  Decreased Peak Expiratory Flow Associated with Muscle Fiber-Type Switching in Spinal and Bulbar Muscular Atrophy.

Authors:  Shinichiro Yamada; Atsushi Hashizume; Yasuhiro Hijikata; Tomonori Inagaki; Keisuke Suzuki; Naohide Kondo; Kaori Kawai; Seiya Noda; Hirotaka Nakanishi; Haruhiko Banno; Akihiro Hirakawa; Haruki Koike; Katherine Halievski; Cynthia L Jordan; Masahisa Katsuno; Gen Sobue
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

8.  Patient-identified impact of symptoms in spinal and bulbar muscular atrophy.

Authors:  Robert D Guber; Angela D Kokkinis; Alice B Schindler; Roxanna M Bendixen; Chad R Heatwole; Kenneth H Fischbeck; Christopher Grunseich
Journal:  Muscle Nerve       Date:  2017-09-25       Impact factor: 3.217

9.  Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy.

Authors:  Yasuhiro Hijikata; Masahisa Katsuno; Keisuke Suzuki; Atsushi Hashizume; Amane Araki; Shinichiro Yamada; Tomonori Inagaki; Madoka Iida; Seiya Noda; Hirotaka Nakanishi; Haruhiko Banno; Tomoo Mano; Akihiro Hirakawa; Hiroaki Adachi; Hirohisa Watanabe; Masahiko Yamamoto; Gen Sobue
Journal:  Ann Clin Transl Neurol       Date:  2016-06-23       Impact factor: 4.511

10.  Highly Elevated Prevalence of Spinobulbar Muscular Atrophy in Indigenous Communities in Canada Due to a Founder Effect.

Authors:  Jamie N Leckie; Matthew M Joel; Kristina Martens; Alexandra King; Malcolm King; Lawrence W Korngut; A P Jason de Koning; Gerald Pfeffer; Kerri L Schellenberg
Journal:  Neurol Genet       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.